Skip to main content
NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · NBY ISIN · US66987P2011 LEI · 549300D5U7PQPNEX8Q38 US Manufacturing
Open in API
Filings indexed 1,026 across all filing types
Latest filing 2024-09-20 Regulatory Filings
Country US United States of America
Listing US NBY

About NovaBay Pharmaceuticals, Inc.

https://novabay.com/

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes scientifically-created and clinically-proven products for the eyecare, skincare, and wound care markets. The company's core technology is a proprietary, stable formulation of hypochlorous acid. Its leading product is Avenova®, an antimicrobial lid and lash solution available over-the-counter for eye hygiene. In the wound care sector, NovaBay manufactures and sells products under the NeutroPhase® and PhaseOne® brands, which utilize its hypochlorous acid technology to aid in cleansing and debridement. The company focuses on providing accessible, problem-solving solutions for improved well-being.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 19, 2024, by NovaBay Pharmaceuticals, Inc. It details the entry into a material definitive agreement for the sale of substantially all operating assets to another company, PRN Physician Recommended Nutriceuticals, LLC. The document includes detailed descriptions of the asset purchase agreement, conditions, representations, warranties, indemnifications, and termination rights. It also mentions the plan to file a proxy statement for stockholder approval of the transaction. The document is a regulatory filing reporting a significant corporate event but does not contain financial statements or detailed financial performance data. It is not an annual or quarterly report, earnings release, or proxy statement itself, but a current report disclosing a material definitive agreement and related corporate actions. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-20 English
FORM 10-Q
Interim / Quarterly Report Q2 2024
2024-08-13 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 29, 2024, reporting the entry into a material definitive agreement related to a public offering of common stock and warrants by NovaBay Pharmaceuticals, Inc. It details the underwriting agreement, terms of the offering, exercise prices, and lock-up agreements. The document also includes press releases announcing the pricing and closing of the offering. There are no financial statements or quarterly/yearly financial results presented. The content focuses on capital raising activities and financing terms. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length is substantial (12,472 characters), and it is not merely an announcement of a report but the actual filing of the event.
2024-07-29 English
FORM 424B4
Capital/Financing Update Classification · 100% confidence The document is a Form 424B4 prospectus filed pursuant to Rule 424(b)(4) under the Securities Act, which is a detailed offering document describing the terms of a securities offering including shares, warrants, pricing, underwriting, and risk factors. It is not a financial report, earnings release, or management discussion. It is a registration/prospectus document related to capital raising and securities issuance. This fits the definition of a Capital/Financing Update (CAP) as it provides detailed information about a new securities offering and related financing terms.
2024-07-27 English
FORM POS EX
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC. It is related to securities registration under the Securities Act of 1933, specifically a post-effective amendment to a registration statement for a securities offering. The document includes legal opinions and consents as exhibits and signatures of officers and directors. It is not a financial report, earnings release, or management discussion. It is a filing related to capital raising and securities registration, which fits the category of Capital/Financing Update (CAP). The document length is about 5993 characters, which is substantive and contains the amendment details, not just an announcement. Therefore, the best classification is CAP with high confidence.
2024-07-26 English
Regulatory Filings 2024
Regulatory Filings
2024-07-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.